Global healthcare leader Abbott has launched the AVEIR VR leadless pacemaker in India, a groundbreaking innovation designed to treat patients with slow heart rhythms. The device, approved by the Central Drugs Standard Control Organisation (CDSCO) and the US Food and Drug Administration (USFDA), offers an advanced solution for cardiac rhythm management.

Unlike traditional pacemakers, the AVEIR VR leadless pacemaker eliminates the need for chest incisions, generator pockets, or insulated wires (known as cardiac leads). Instead, it is directly implanted into the heart, significantly reducing complications commonly associated with conventional pacemakers.

Ajay Singh Chauhan, General Manager for Abbott’s Cardiac Rhythm Management division in India and other regions, highlighted the innovation, stating, “The AVEIR VR leadless pacemaker was designed to make implantation and retrieval processes as seamless as possible for physicians while providing advancements over existing options.”

Leadless pacemakers are particularly beneficial for patients experiencing slower-than-normal heart rhythms by delivering electrical pulses to regulate the heart’s beats effectively.

Dr. Balbir Singh, Chairman of Cardiology at Max Super Speciality Hospital, noted the advantages of this technology, stating, “Leadless pacemakers address known complications associated with traditional pacemakers.” He explained that conventional devices require surgical pockets and cardiac leads, which the new technology eliminates, simplifying the process for both patients and physicians.

Additionally, Dr. Vanita Arora, Clinical Lead for Electrophysiology at Apollo Hospitals Delhi, emphasized the importance of retrievability in specific cases, adding, “In situations where a patient’s therapy needs may evolve, retrievability becomes a critical feature of the device.”

Also Read: Dr. Soumya Swaminathan Honored with FABA Lifetime Achievement Award

Abbott’s AVEIR VR leadless pacemaker represents a significant step forward in cardiac care, offering a safer and more efficient alternative for patients with slow heart rhythms. By introducing this advanced technology, Abbott reaffirms its commitment to improving patient outcomes and advancing healthcare innovation in India.

This launch positions Abbott at the forefront of cardiac rhythm management, addressing evolving patient needs while enhancing the quality of care across the country.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!